Author:
Dabour Mohamed S.,Abdelgawad Ibrahim Y.,Grant Marianne K.O.,El-Sawaf Engie S.,Zordoky Beshay N.
Funder
Ministry of Higher Education
USAID Egypt
University of Minnesota
Ministry of Higher Education, Egypt
United States Agency for International Development
College of Pharmacy, University of Minnesota
University of Minnesota Twin Cities Graduate School
Subject
Pharmacology,General Medicine
Reference83 articles.
1. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management;Vincent Rajkumar;Am. J. Hematol.,2014
2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008
3. Carfilzomib: a novel second-generation proteasome inhibitor;Khan;Future Oncol.,2011
4. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma;Fostier;Onco Targets Ther.,2012
5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study;Dimopoulos;Lancet Oncol.,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献